Loading…
Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia
Sleep disruption and other circadian rhythm disturbances are frequently seen in dementia patients. In this study, we examined the suprachiasmatic nucleus (SCN), the putative site of the hypothalamic circadian pacemaker, to determine the nature and degree of pathologic changes caused by severe dement...
Saved in:
Published in: | Journal of neuropathology and experimental neurology 1999-01, Vol.58 (1), p.29-39 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5984-89c17fce6ce9bc1f4c650e8999dbdf8a9e50a261f213782af13264e86b163acd3 |
---|---|
cites | |
container_end_page | 39 |
container_issue | 1 |
container_start_page | 29 |
container_title | Journal of neuropathology and experimental neurology |
container_volume | 58 |
creator | Stopa, Edward G Volicer, Ladislav Kuo-Leblanc, Victoria Harper, David Lathi, Devayani Tate, Barbara Satlin, Andrew |
description | Sleep disruption and other circadian rhythm disturbances are frequently seen in dementia patients. In this study, we examined the suprachiasmatic nucleus (SCN), the putative site of the hypothalamic circadian pacemaker, to determine the nature and degree of pathologic changes caused by severe dementia. Neuropathologic examination indicated that among 30 patients with a clinical history of severe dementia, 22 had Braak and Braak stage V-VI Alzheimer disease, 3 had combined Alzheimer and Parkinson disease, 3 had Pick disease and 2 had severe hippocampal sclerosis. Comparisons were made with a control group composed of 13 age-matched patients with no clinical or pathological evidence of dementia or other CNS disorders. To determine the pathologic involvement within the SCN, human hypothalami were stained withNissl, Bielchowsky silver, thioflavin S and specific antibodies directed against vasopressin (VP), neurotensin (NT), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), beta-amyloid (B/A4) and glial fibrillary acidic protein (GFAP). Pathologic damage was primarily limited to neuronal loss and neurofibrillary tangle formation. Only rare diffuse plaques were noted. The pathologic changes within the SCN were less severe than in the other brain regions. Morphometric analysis was accomplished using a stereological approach to sample the average total number of positively stained neurons and astrocytes in 10 different 0.1mm2 microscopic fields in the dorsal subdivision of the SCN. Patients with Alzheimer disease exhibited a significant decrease in vasopressin (9.75 vs 16.7, p |
doi_str_mv | 10.1097/00005072-199901000-00004 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69576255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A536176833</galeid><sourcerecordid>A536176833</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5984-89c17fce6ce9bc1f4c650e8999dbdf8a9e50a261f213782af13264e86b163acd3</originalsourceid><addsrcrecordid>eNqFkl1vFSEQhonR2NPqXzAbY7zbCiywcNm0tTWpH4l6TTjs0KWyyxGWNv57qXv8iIkRLggzzzth5gWhhuBjglX_CtfFcU9bopTCpN7a-xB7gDaEc9YK3suHaIMxpW2HhTpAhznfVEJhxR6jg6oQsiNkg95-MMsYQ7z2tjm_NaGYxce5ia5ZRmguy2Tm5mPZJWNHb_JUs7Z5V2yAkhtfU3ALCZozmGBevHmCHjkTMjzdn0fo8-vzT6eX7dX7izenJ1et5UqyVipLemdBWFBbSxyzgmOQtZdhOzhpFHBsqCCOkq6X1DjSUcFAii0RnbFDd4RernV3KX4tkBc9-WwhBDNDLFkLxXtBOf8vSBQjkklZwed_gTexpLk2oSlVPakF-wodr9C1CaD97OJSB1P3AJO3cQbna_yEd4L0db5dFchVYFPMOYHTu-Qnk75pgvW9k_qnk_qXkz9CrEqf7R9UthMMfwhX6yrwYg-YbE1wyczW59-cEHV4uGJsxe5iWCDlL6HcQdIjmLCM-l8fqfsOhGezig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229719577</pqid></control><display><type>article</type><title>Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia</title><source>Oxford Journals Online</source><creator>Stopa, Edward G ; Volicer, Ladislav ; Kuo-Leblanc, Victoria ; Harper, David ; Lathi, Devayani ; Tate, Barbara ; Satlin, Andrew</creator><creatorcontrib>Stopa, Edward G ; Volicer, Ladislav ; Kuo-Leblanc, Victoria ; Harper, David ; Lathi, Devayani ; Tate, Barbara ; Satlin, Andrew</creatorcontrib><description>Sleep disruption and other circadian rhythm disturbances are frequently seen in dementia patients. In this study, we examined the suprachiasmatic nucleus (SCN), the putative site of the hypothalamic circadian pacemaker, to determine the nature and degree of pathologic changes caused by severe dementia. Neuropathologic examination indicated that among 30 patients with a clinical history of severe dementia, 22 had Braak and Braak stage V-VI Alzheimer disease, 3 had combined Alzheimer and Parkinson disease, 3 had Pick disease and 2 had severe hippocampal sclerosis. Comparisons were made with a control group composed of 13 age-matched patients with no clinical or pathological evidence of dementia or other CNS disorders. To determine the pathologic involvement within the SCN, human hypothalami were stained withNissl, Bielchowsky silver, thioflavin S and specific antibodies directed against vasopressin (VP), neurotensin (NT), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), beta-amyloid (B/A4) and glial fibrillary acidic protein (GFAP). Pathologic damage was primarily limited to neuronal loss and neurofibrillary tangle formation. Only rare diffuse plaques were noted. The pathologic changes within the SCN were less severe than in the other brain regions. Morphometric analysis was accomplished using a stereological approach to sample the average total number of positively stained neurons and astrocytes in 10 different 0.1mm2 microscopic fields in the dorsal subdivision of the SCN. Patients with Alzheimer disease exhibited a significant decrease in vasopressin (9.75 vs 16.7, p<0.001) and neurotensin (6.82 vs 9.63, p<0.002) neurons, as well as a corresponding increase in the GFAP-stained astrocyte/Nissl-stained neuron ratio (0.54 vs 0.10, p<0.009). These studies provide evidence that both vasopressin and neurotensin neurons are lost in Alzheimer disease, and that the astrocyte/neuron ratio is a reliable indicator of disease-related pathology within the SCN. Taken collectively, our data support the hypothesis that damage to the SCN may be an underlying anatomical substrate for the clinically observed changes in circadian rhythmicity that have been observed in Alzheimer patients.</description><identifier>ISSN: 0022-3069</identifier><identifier>EISSN: 1554-6578</identifier><identifier>DOI: 10.1097/00005072-199901000-00004</identifier><identifier>PMID: 10068311</identifier><identifier>CODEN: JNENAD</identifier><language>eng</language><publisher>Hagerstown, MD: American Association of Neuropathologists, Inc</publisher><subject>Alzheimer's disease ; Analysis ; Biological and medical sciences ; Case-Control Studies ; Circadian Rhythm - physiology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dementia ; Dementia - pathology ; Evaluation Studies as Topic ; Humans ; Immunohistochemistry ; Male ; Medical research ; Medical sciences ; Middle Aged ; Neuroglia - pathology ; Neurology ; Neurons - pathology ; Neuropeptide Y ; Neurotensin ; Parkinson disease ; Suprachiasmatic Nucleus - pathology ; Vasoactive intestinal peptides</subject><ispartof>Journal of neuropathology and experimental neurology, 1999-01, Vol.58 (1), p.29-39</ispartof><rights>1999 American Association of Neuropathologists, Inc</rights><rights>1999 INIST-CNRS</rights><rights>COPYRIGHT 1999 Oxford University Press</rights><rights>Copyright American Association of Neuropathologists, Inc. Jan 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5984-89c17fce6ce9bc1f4c650e8999dbdf8a9e50a261f213782af13264e86b163acd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1661370$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10068311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stopa, Edward G</creatorcontrib><creatorcontrib>Volicer, Ladislav</creatorcontrib><creatorcontrib>Kuo-Leblanc, Victoria</creatorcontrib><creatorcontrib>Harper, David</creatorcontrib><creatorcontrib>Lathi, Devayani</creatorcontrib><creatorcontrib>Tate, Barbara</creatorcontrib><creatorcontrib>Satlin, Andrew</creatorcontrib><title>Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia</title><title>Journal of neuropathology and experimental neurology</title><addtitle>J Neuropathol Exp Neurol</addtitle><description>Sleep disruption and other circadian rhythm disturbances are frequently seen in dementia patients. In this study, we examined the suprachiasmatic nucleus (SCN), the putative site of the hypothalamic circadian pacemaker, to determine the nature and degree of pathologic changes caused by severe dementia. Neuropathologic examination indicated that among 30 patients with a clinical history of severe dementia, 22 had Braak and Braak stage V-VI Alzheimer disease, 3 had combined Alzheimer and Parkinson disease, 3 had Pick disease and 2 had severe hippocampal sclerosis. Comparisons were made with a control group composed of 13 age-matched patients with no clinical or pathological evidence of dementia or other CNS disorders. To determine the pathologic involvement within the SCN, human hypothalami were stained withNissl, Bielchowsky silver, thioflavin S and specific antibodies directed against vasopressin (VP), neurotensin (NT), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), beta-amyloid (B/A4) and glial fibrillary acidic protein (GFAP). Pathologic damage was primarily limited to neuronal loss and neurofibrillary tangle formation. Only rare diffuse plaques were noted. The pathologic changes within the SCN were less severe than in the other brain regions. Morphometric analysis was accomplished using a stereological approach to sample the average total number of positively stained neurons and astrocytes in 10 different 0.1mm2 microscopic fields in the dorsal subdivision of the SCN. Patients with Alzheimer disease exhibited a significant decrease in vasopressin (9.75 vs 16.7, p<0.001) and neurotensin (6.82 vs 9.63, p<0.002) neurons, as well as a corresponding increase in the GFAP-stained astrocyte/Nissl-stained neuron ratio (0.54 vs 0.10, p<0.009). These studies provide evidence that both vasopressin and neurotensin neurons are lost in Alzheimer disease, and that the astrocyte/neuron ratio is a reliable indicator of disease-related pathology within the SCN. Taken collectively, our data support the hypothesis that damage to the SCN may be an underlying anatomical substrate for the clinically observed changes in circadian rhythmicity that have been observed in Alzheimer patients.</description><subject>Alzheimer's disease</subject><subject>Analysis</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Circadian Rhythm - physiology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dementia</subject><subject>Dementia - pathology</subject><subject>Evaluation Studies as Topic</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuroglia - pathology</subject><subject>Neurology</subject><subject>Neurons - pathology</subject><subject>Neuropeptide Y</subject><subject>Neurotensin</subject><subject>Parkinson disease</subject><subject>Suprachiasmatic Nucleus - pathology</subject><subject>Vasoactive intestinal peptides</subject><issn>0022-3069</issn><issn>1554-6578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkl1vFSEQhonR2NPqXzAbY7zbCiywcNm0tTWpH4l6TTjs0KWyyxGWNv57qXv8iIkRLggzzzth5gWhhuBjglX_CtfFcU9bopTCpN7a-xB7gDaEc9YK3suHaIMxpW2HhTpAhznfVEJhxR6jg6oQsiNkg95-MMsYQ7z2tjm_NaGYxce5ia5ZRmguy2Tm5mPZJWNHb_JUs7Z5V2yAkhtfU3ALCZozmGBevHmCHjkTMjzdn0fo8-vzT6eX7dX7izenJ1et5UqyVipLemdBWFBbSxyzgmOQtZdhOzhpFHBsqCCOkq6X1DjSUcFAii0RnbFDd4RernV3KX4tkBc9-WwhBDNDLFkLxXtBOf8vSBQjkklZwed_gTexpLk2oSlVPakF-wodr9C1CaD97OJSB1P3AJO3cQbna_yEd4L0db5dFchVYFPMOYHTu-Qnk75pgvW9k_qnk_qXkz9CrEqf7R9UthMMfwhX6yrwYg-YbE1wyczW59-cEHV4uGJsxe5iWCDlL6HcQdIjmLCM-l8fqfsOhGezig</recordid><startdate>199901</startdate><enddate>199901</enddate><creator>Stopa, Edward G</creator><creator>Volicer, Ladislav</creator><creator>Kuo-Leblanc, Victoria</creator><creator>Harper, David</creator><creator>Lathi, Devayani</creator><creator>Tate, Barbara</creator><creator>Satlin, Andrew</creator><general>American Association of Neuropathologists, Inc</general><general>Lippincott Williams & Wilkins</general><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>199901</creationdate><title>Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia</title><author>Stopa, Edward G ; Volicer, Ladislav ; Kuo-Leblanc, Victoria ; Harper, David ; Lathi, Devayani ; Tate, Barbara ; Satlin, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5984-89c17fce6ce9bc1f4c650e8999dbdf8a9e50a261f213782af13264e86b163acd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Alzheimer's disease</topic><topic>Analysis</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Circadian Rhythm - physiology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dementia</topic><topic>Dementia - pathology</topic><topic>Evaluation Studies as Topic</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuroglia - pathology</topic><topic>Neurology</topic><topic>Neurons - pathology</topic><topic>Neuropeptide Y</topic><topic>Neurotensin</topic><topic>Parkinson disease</topic><topic>Suprachiasmatic Nucleus - pathology</topic><topic>Vasoactive intestinal peptides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stopa, Edward G</creatorcontrib><creatorcontrib>Volicer, Ladislav</creatorcontrib><creatorcontrib>Kuo-Leblanc, Victoria</creatorcontrib><creatorcontrib>Harper, David</creatorcontrib><creatorcontrib>Lathi, Devayani</creatorcontrib><creatorcontrib>Tate, Barbara</creatorcontrib><creatorcontrib>Satlin, Andrew</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuropathology and experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stopa, Edward G</au><au>Volicer, Ladislav</au><au>Kuo-Leblanc, Victoria</au><au>Harper, David</au><au>Lathi, Devayani</au><au>Tate, Barbara</au><au>Satlin, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia</atitle><jtitle>Journal of neuropathology and experimental neurology</jtitle><addtitle>J Neuropathol Exp Neurol</addtitle><date>1999-01</date><risdate>1999</risdate><volume>58</volume><issue>1</issue><spage>29</spage><epage>39</epage><pages>29-39</pages><issn>0022-3069</issn><eissn>1554-6578</eissn><coden>JNENAD</coden><abstract>Sleep disruption and other circadian rhythm disturbances are frequently seen in dementia patients. In this study, we examined the suprachiasmatic nucleus (SCN), the putative site of the hypothalamic circadian pacemaker, to determine the nature and degree of pathologic changes caused by severe dementia. Neuropathologic examination indicated that among 30 patients with a clinical history of severe dementia, 22 had Braak and Braak stage V-VI Alzheimer disease, 3 had combined Alzheimer and Parkinson disease, 3 had Pick disease and 2 had severe hippocampal sclerosis. Comparisons were made with a control group composed of 13 age-matched patients with no clinical or pathological evidence of dementia or other CNS disorders. To determine the pathologic involvement within the SCN, human hypothalami were stained withNissl, Bielchowsky silver, thioflavin S and specific antibodies directed against vasopressin (VP), neurotensin (NT), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), beta-amyloid (B/A4) and glial fibrillary acidic protein (GFAP). Pathologic damage was primarily limited to neuronal loss and neurofibrillary tangle formation. Only rare diffuse plaques were noted. The pathologic changes within the SCN were less severe than in the other brain regions. Morphometric analysis was accomplished using a stereological approach to sample the average total number of positively stained neurons and astrocytes in 10 different 0.1mm2 microscopic fields in the dorsal subdivision of the SCN. Patients with Alzheimer disease exhibited a significant decrease in vasopressin (9.75 vs 16.7, p<0.001) and neurotensin (6.82 vs 9.63, p<0.002) neurons, as well as a corresponding increase in the GFAP-stained astrocyte/Nissl-stained neuron ratio (0.54 vs 0.10, p<0.009). These studies provide evidence that both vasopressin and neurotensin neurons are lost in Alzheimer disease, and that the astrocyte/neuron ratio is a reliable indicator of disease-related pathology within the SCN. Taken collectively, our data support the hypothesis that damage to the SCN may be an underlying anatomical substrate for the clinically observed changes in circadian rhythmicity that have been observed in Alzheimer patients.</abstract><cop>Hagerstown, MD</cop><pub>American Association of Neuropathologists, Inc</pub><pmid>10068311</pmid><doi>10.1097/00005072-199901000-00004</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3069 |
ispartof | Journal of neuropathology and experimental neurology, 1999-01, Vol.58 (1), p.29-39 |
issn | 0022-3069 1554-6578 |
language | eng |
recordid | cdi_proquest_miscellaneous_69576255 |
source | Oxford Journals Online |
subjects | Alzheimer's disease Analysis Biological and medical sciences Case-Control Studies Circadian Rhythm - physiology Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dementia Dementia - pathology Evaluation Studies as Topic Humans Immunohistochemistry Male Medical research Medical sciences Middle Aged Neuroglia - pathology Neurology Neurons - pathology Neuropeptide Y Neurotensin Parkinson disease Suprachiasmatic Nucleus - pathology Vasoactive intestinal peptides |
title | Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A53%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathologic%20Evaluation%20of%20the%20Human%20Suprachiasmatic%20Nucleus%20in%20Severe%20Dementia&rft.jtitle=Journal%20of%20neuropathology%20and%20experimental%20neurology&rft.au=Stopa,%20Edward%20G&rft.date=1999-01&rft.volume=58&rft.issue=1&rft.spage=29&rft.epage=39&rft.pages=29-39&rft.issn=0022-3069&rft.eissn=1554-6578&rft.coden=JNENAD&rft_id=info:doi/10.1097/00005072-199901000-00004&rft_dat=%3Cgale_proqu%3EA536176833%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5984-89c17fce6ce9bc1f4c650e8999dbdf8a9e50a261f213782af13264e86b163acd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=229719577&rft_id=info:pmid/10068311&rft_galeid=A536176833&rfr_iscdi=true |